Wanbury Ltd. (BSE: 524212) is a Navi Mumbai, Maharashtra-based company in the Pharmaceuticals industry. With a market capitalisation of ₹699 Cr, it ranks #1,809 by market cap among the 6,197 Indian listed companies on FinBizNet, and #26 of 63 in Pharmaceuticals. At ₹192.20 (as of 16 Nov 2026), the share price is 46.4% below its 52-week high of ₹358.85 and 19.0% above its 52-week low of ₹161.50. The share price is down 21.8% over one year and down 23.0% over three months.
| Current Price | ₹192.20 |
|---|---|
| Market Cap | ₹699 Cr |
| BSE Code | 524212 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 10.4 |
| Return on Equity | 64.92% |
| Return on Assets | 12.40% |
| 52-Week Range | ₹161.50 – ₹358.85 |
| 1-Year Price Change | -21.8% |
| 3-Month Price Change | -23.0% |
| Beta (1Y) | 0.36 |
| Dividend Yield | 0.00% |
| Headquarters | Navi Mumbai, Maharashtra |
| Website | www.wanbury.com |
| Revenue | ₹183 Cr |
|---|---|
| Net Profit | ₹9 Cr |
| Net Margin | 4.7% |
| EPS (Basic) | ₹2.44 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Promoters held 42.98% of Wanbury Ltd.'s shares as of Sept 2026, against 43.09% in Sept 2025 (−0.11 percentage points). Delivery averaged 48.3% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. The company offers formulations for anti-infectives, pain and analgesics, respiratory, gastroenterology, gynecology, rheumatology, and central nervous system, as well as for vitamins, minerals, and nutrition. It also provides API products for antidiabetics, antihistamines, antitussives, analgesics, antidepressants, and anti-inflammatory medicines. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. Wanbury Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.
1. Pharmaceuticals and Related Products-This segment manufactures and sells formulations and active pharmaceutical ingredients.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Wanbury Ltd. | ₹699 Cr | 10.4 | 64.92% | ₹183 Cr | -21.8% |
Listed by market capitalisation. Ratios are shown for context only.
Wanbury Ltd. is trading at ₹192.20, with a market capitalisation of ₹699 Cr.
Wanbury Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Wanbury Ltd. has a P/E of 10.4 and a return on equity of 64.92%.
Wanbury Ltd. is listed on the BSE under the scrip code 524212.
Wanbury Ltd.'s share price is down 21.8% over one year and down 23.0% over three months. Its 52-week range is ₹161.50 to ₹358.85.
In Q2 FY27, Wanbury Ltd. reported revenue of ₹183 Cr and net profit of ₹9 Cr, with basic EPS of ₹2.44 (consolidated, parsed from the company's exchange filing).
Promoters held 42.98% of Wanbury Ltd.'s shares as of Sept 2026, against 43.09% in Sept 2025 (−0.11 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.